Jason Tardio adds role at Immunic to impressive CV

9 July 2024

Immunic (Nasdaq: IMUX), a US biotech developing a pipeline of orally-administered, small molecule therapies for chronic inflammatory and autoimmune diseases, has appointed experienced biopharma executive Jason Tardio as chief operating officer and president.

In the newly-created role, Mr. Tardio will lead internal efforts to prepare for the potential launch of vidofludimus calcium, the company’s orally available nuclear receptor related 1 activator. 

He will also work closely with chief business officer Patrick Walsh to prepare the firm for a range of potential partnership outcomes for vidofludimus calcium, as well as Immunic’s other drug candidates. 

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology